BridgeBio Pharma, Inc. (BBIO) Stock

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

BridgeBio Pharma, Inc. is led by CEO Neil Kumar, employs 839 people, headquartered in Palo Alto, US, publicly traded since 2019.

BridgeBio Pharma, Inc. (BBIO) stock trades at $68.56 with a market capitalization of $13.40B. The stock is valued at a negative price-to-earnings (P/E) ratio of -18.58, reflecting a net loss over the last twelve months, a negative price-to-book of -5.18, reflecting negative shareholders' equity, price-to-sales of 18.27. Over the past 52 weeks the stock has ranged between $52.75 and $93.42, and currently trades 26.6% below its 52-week high.

On profitability, BridgeBio Pharma, Inc. generates a return on equity (ROE) of 31.67% (not meaningful, as shareholders' equity is negative), return on capital employed of -87.81%, an operating margin of -113.35%, a net profit margin of -97.64%.

Official website: www.bridgebio.com

BridgeBio Pharma, Inc. by the numbers, 2017–2025

Between 2017 and 2025 BridgeBio Pharma, Inc. reported revenue of $0 rising to $502.0M. Compounded, revenue has grown 128.8% a year over five years, 86.0% over three, 126.1% over the last twelve months. Net profit fell to $-729.0M.

The most recent net margin is -97.64%. On a trailing twelve-month basis to Jun '26, revenue is $692.0M and net profit $-696.0M.

Borrowings rose from $144.0M to $2.7B, cash from operations was $-446.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged 44.4% over five years, and was 35.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

BridgeBio Pharma, Inc. (BBIO) — frequently asked questions